Study Evaluating Betrixaban in Pediatric Participants

Phase 1 Terminated 21 enrolled Alexion Pharmaceuticals, Inc. Portola Pharmaceuticals, LLC (a wholly owned subsidiary of Alexion Pharmaceuticals) · collab

Non-randomizedParallel-groupOpen-labelTreatment

Summary

This trial was a Phase 1, open-label, multicenter study of the pharmacokinetics (PK), pharmacodynamics (PD), and safety of a single dose of betrixaban in pediatric participants at risk of venous thromboembolism (VTE).

Timeline

Start: 2018-07-13
Primary completion: 2019-10-08
Completion: 2019-10-08

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Betrixaban	Small molecule	40 mg	Oral
Subject	Betrixaban	Small molecule	80 mg	Oral

Indications

No indication recorded.